Floatz logo

Febuxostat

Diastolic Heart Failure

National Defense Medical Center, TaiwanSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Diastolic Heart Failure cohort.

Asset / SponsorPhaseRating
Semaglutide
Mayo Clinic
Phase 4BBB
Metformin
Sara ElAdawy
Phase 4BBB
Tirzepatide
Yunlong Wang
Phase 4BBB
Liraglutide
Leiden University Medical Center
Phase 4BBB
BENZBROMARONE
National Defense Medical Center, Taiwan
Phase 4BB

View all 23 →

Same molecule, other indications

Febuxostat is also rated in:

goutDormant
BBB
Indicative ·
72 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
66 / 100
View asset →
tumor lysis syndromeDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →